MK-1084 + proton pump inhibitor

MK-1084 + proton pump inhibitor is a combination of **MK-1084**, an investigational small molecule targeted covalent inhibitor of KRAS G12C, and a **proton pump inhibitor** (PPI, a class of drugs that suppress gastric acid secretion). MK-1084 is being developed primarily for advanced or metastatic solid tumors harboring the KRAS G12C mutation, especially colorectal cancer and non-small cell lung cancer. Its mechanism is highly selective inhibition of KRAS G12C, locking the mutant protein in an inactive state and blocking downstream oncogenic signaling. There are no clinical studies or evidence in the provided sources specifically involving MK-1084 in combination with a proton pump inhibitor, nor is the combination an established or named regimen. Proton pump inhibitors are commonly co-administered with anticancer agents for gastric protection but do not directly bind KRAS or modify its oncogenic function. MK-1084 is developed by Merck with collaborative agreements involving Taiho Pharmaceutical and Astex Pharmaceuticals (Otsuka). No brand names or code names exist for the combination as a unique product.